All In Biotech

Drug Trial Radar · NCT05464030

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

220

Actual

Start

Aug 4, 2022

Primary completion

Oct 23, 2026

Study completion Oct 23, 2026

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jul 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this first in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2) Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program

Conditions

  • Colorectal Cancer

Interventions

  • M9140Drug

    M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Part 1 of the study.

  • M9140Drug

    M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.

  • BevacizumabDrug

    Bevacizumab will be administered intravenously as per standard of care.

  • CapecitabineDrug

    Capecitabine will be administered orally as per standard of care.

  • 5-fluorouracil (5-FU)Drug

    5-FU will be administered intravenously as per standard of care.

  • Folinic acidDrug

    Folinic acid will be administered intravenously as per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)Time frame: up to 4 months
  2. Part 1: Recommended Dose Expansion (RDE) of M9140Time frame: up to 4 months
  3. Parts 2B, 2C and 2D: Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)Time frame: up to 8 months
  4. Part 2A: Number of Participants with Adverse Events (AEs)Time frame: up to 8 months
  5. Part 2A: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by InvestigatorsTime frame: Time from first study treatment throughout the study duration until progressive disease or death up to approximately 8 months
  6. Part 2A: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by InvestigatorsTime frame: Time from first study treatment to planned assessment at approximately 8 months

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • California Cancer Associates for Research & Excellence, Inc.

    Encinitas, California

  • California Cancer Associates for Research & Excellence, Inc.

    Fresno, California

  • Rhode Island Hospital

    Providence, Rhode Island

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson Cancer Center - Oncology

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

  • The Ottawa Hospital Cancer Centre

    Ottawa, Canada

  • University Health Network - Princess Margaret Cancer Centre

    Toronto, Canada

  • National Cancer Center Hospital - Dept of Gastroenterology

    Chūōku, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, Japan

  • Saitama Cancer Center

    Kitaadachi-gun, Japan

  • Cancer Institute Hospital of JFCR

    Kōtoku, Japan

  • Aichi Cancer Center Hospital

    Nagoya, Japan

  • Kindai University Hospital

    Osakasayama-shi, Japan

  • Shizuoka Cancer Center

    Sunto-gun, Japan

  • Kanagawa Cancer Center

    Yokohama, Japan

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea

  • National Cancer Center

    Goyang-si, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital del Mar

    Barcelona, Spain

  • Hospital HM Nou Delfos

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron - VHIR

    Barcelona, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

  • ICO l'Hospitalet - Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Spain

  • Centro Integral Oncologico Clara Campal

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario Quironsalud Madrid - NEXT Oncology

    Madrid, Spain

  • Complejo Hospitalario Universitario de Santiago

    Santiago de Compostela, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.